Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis

Hanft, Jason R.; Surprenant, Maria S.

doi:10.1016/s1067-2516(02)80047-3

Cited by 107 publications

(70 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The fibroblasts in this material are able to generate growth factors, collagen, cytokines, and glycosaminoglycans to help support the wound healing environment. Numerous studies have borne out its efficacy [46, 47], especially for burn wounds and venous/pressure ulcers, but a few downsides are a theoretical risk of rejection (although unreported thus far) and hypersensitivity (as bovine serum may be contained in trace amounts in the preparation). This concept was taken one step further with Apligraf, an allogenic bilayered cultured skin equivalent, where a dermal layer of cultured fibroblasts and bovine type I collagen is combined with an epidermal layer of cultured keratinocytes, generating a material that can be absorbed much like a graft and generates a similar environment to a normally healing wound.…”

Section: Skin Substitutesmentioning

confidence: 99%

Chronic Wound Healing: A Review of Current Management and Treatments

2017

View full text Add to dashboard Cite

Wound healing is a complex, highly regulated process that is critical in maintaining the barrier function of skin. With numerous disease processes, the cascade of events involved in wound healing can be affected, resulting in chronic, non-healing wounds that subject the patient to significant discomfort and distress while draining the medical system of an enormous amount of resources. The healing of a superficial wound requires many factors to work in concert, and wound dressings and treatments have evolved considerably to address possible barriers to wound healing, ranging from infection to hypoxia. Even optimally, wound tissue never reaches its pre-injured strength and multiple aberrant healing states can result in chronic non-healing wounds. This article will review wound healing physiology and discuss current approaches for treating a wound.

show abstract

Section: Skin Substitutesmentioning

confidence: 99%

Chronic Wound Healing: A Review of Current Management and Treatments

2017

View full text Add to dashboard Cite

show abstract

“…[2][3][4][5][6] The advantage of a living skin substitute above an acellular dressing is now widely accepted: living skin substitutes secrete a cocktail of cytokines, chemokines and growth factors which promote wound healing (by stimulating angiogenesis, granulation tissue formation and epithelialization) as well as providing an immediate cover for the wound. There are currently three categories of living skin substitute available: allogeneic or autologous fibroblastpopulated dermal substitutes, 7,8 allogeneic or autologous epidermal substitutes [9][10][11] and allogeneic full skin substitutes (allogeneic epidermis on allogeneic fibroblast-populated bovine collagen gels). 12 No autologous, full-thickness skin substitute of entirely human origin and which closely resembles a native autograft (frequently used in acute wound healing) is available.…”

mentioning

confidence: 99%

Autologous full-thickness skin substitute for healing chronic wounds

Gibbs

Hoogenband

Kirtschig

et al. 2006

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…According to the latest statistics for 2003, diabetic foot ulcers occurred in 1.2% of patients with diabetes foot disease, which is 47.9% of all cases of foot disease, 54.4% of all cases of foot amputation [1,4]. …”

Section: Discussionmentioning

confidence: 99%

Treatment of Diabetic Foot Ulcer Using Matriderm In Comparison with a Skin Graft

et al. 2013

View full text Add to dashboard Cite

BackgroundFor patients with neuropathy, vasculopathy, and impairment of wound healing, treatment of a diabetic foot ulcer poses many challenges. A large number of dermal analogues have been invented in an effort to overcome these challenges. Matriderm, a dermal analogue, is made from bovine collagen and elastin. This study was conducted in order to evaluate the effectiveness of Matriderm for treatment of diabetic foot ulcers, in comparison with skin grafting.MethodsSixty patients with diabetic foot ulcer were included in this prospective study. The average age of the patients, who had type II diabetes mellitus, was 58 years old. The patients were allocated to an experimental or control group with their consents. The patients were selected with their consent for inclusion in an experimental group and a control group. Patients in the experimental group received a Matriderm appliance and a split-thickness skin graft, while those in the control group received only a split-thickness skin graft.ResultsA shorter hospitalization period (7.52 weeks) was observed in the experimental group than in the control group (9.22 weeks), and a shorter period of time (8.61 weeks) was required for complete healing, compared with the control group (12.94 weeks), with statistical significance (P<0.05). A higher elasticity ratio of the affected side to the non-affected side was observed in the experimental group, compared with the control group (P<0.01).ConclusionsMatriderm enables effective healing and improves elasticity in treatment of patients with diabetic foot ulcer.

show abstract

Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis

Cited by 107 publications

References 4 publications

Chronic Wound Healing: A Review of Current Management and Treatments

Chronic Wound Healing: A Review of Current Management and Treatments

Autologous full-thickness skin substitute for healing chronic wounds

Treatment of Diabetic Foot Ulcer Using Matriderm In Comparison with a Skin Graft

Contact Info

Product

Resources

About